{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.1","upperLimit":"12.9","value":"9.6"},{"groupId":"OG001","lowerLimit":"6.7","upperLimit":"8.3","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"599"},{"groupId":"OG001","value":"599"}],"units":"Participants"}],"description":"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).\n\nPatients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab intravenous infusion of 400mg/m\\^2 for the first infusion then weekly intravenous infusion of 250mg/m\\^2. Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"OG000","title":"Cetuximab Plus FOLFIRI"},{"description":"Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"OG001","title":"FOLFIRI Alone"}],"paramType":"MEDIAN","populationDescription":"ITT population (allocation to treatment groups as randomized and treated)","reportingStatus":"POSTED","timeFrame":"Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006","title":"Duration of Response - Independent Review Committee (IRC) Assessments","type":"SECONDARY","unitOfMeasure":"months"}